124 related articles for article (PubMed ID: 38087705)
1. Prospective Longitudinal Assessment of Quality of Life After Stereotactic Ablative Radiotherapy for Oligometastases: Analysis of the Population-based SABR-5 Phase II Trial.
Cruz-Lim EM; Mou B; Baker S; Arbour G; Stefanyk K; Jiang W; Liu M; Bergman A; Schellenberg D; Alexander A; Berrang T; Bang A; Chng N; Matthews Q; Carolan H; Hsu F; Miller S; Atrchian S; Chan E; Ho C; Mohamed I; Lin A; Huang V; Mestrovic A; Hyde D; Lund C; Pai H; Valev B; Lefresne S; Tyldesley S; Olson R
Clin Oncol (R Coll Radiol); 2024 Mar; 36(3):148-156. PubMed ID: 38087705
[TBL] [Abstract][Full Text] [Related]
2. Predictors of Quality of Life Decline in Patients with Oligometastases treated with Stereotactic Ablative Radiotherapy: Analysis of the Population-Based SABR-5 Phase II Trial.
Cruz-Lim EM; Mou B; Jiang W; Liu M; Bergman A; Schellenberg D; Alexander A; Berrang T; Bang A; Chng N; Matthews Q; Carolan H; Hsu F; Miller S; Atrchian S; Chan E; Ho C; Mohamed I; Lin A; Huang V; Mestrovic A; Hyde D; Lund C; Pai H; Valev B; Lefresne S; Tyldesley S; Olson R; Baker S
Clin Oncol (R Coll Radiol); 2024 Mar; 36(3):141-147. PubMed ID: 38296662
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial.
Siva S; Bressel M; Murphy DG; Shaw M; Chander S; Violet J; Tai KH; Udovicich C; Lim A; Selbie L; Hofman MS; Kron T; Moon D; Goad J; Lawrentschuk N; Foroudi F
Eur Urol; 2018 Oct; 74(4):455-462. PubMed ID: 30227924
[TBL] [Abstract][Full Text] [Related]
4. Single vs. multiple fraction non-inferiority trial of stereotactic ablative radiotherapy for the comprehensive treatment of oligo-metastases/progression: SIMPLIFY-SABR-COMET.
Olson R; Abraham H; Leclerc C; Benny A; Baker S; Matthews Q; Chng N; Bergman A; Mou B; Dunne EM; Schellenberg D; Jiang W; Chan E; Atrchian S; Lefresne S; Carolan H; Valev B; Tyldesley S; Bang A; Berrang T; Clark H; Hsu F; Louie AV; Warner A; Palma DA; Howell D; Barry A; Dawson L; Grendarova P; Walker D; Sinha R; Tsai J; Bahig H; Thibault I; Koul R; Senthi S; Phillips I; Grose D; Kelly P; Armstrong J; McDermott R; Johnstone C; Vasan S; Aherne N; Harrow S; Liu M
BMC Cancer; 2024 Feb; 24(1):171. PubMed ID: 38310262
[TBL] [Abstract][Full Text] [Related]
5. Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer: Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial.
Olson R; Jiang W; Liu M; Bergman A; Schellenberg D; Mou B; Alexander A; Carolan H; Hsu F; Miller S; Atrchian S; Chan E; Ho C; Mohamed I; Lin A; Berrang T; Bang A; Chng N; Matthews Q; Baker S; Huang V; Mestrovic A; Hyde D; Lund C; Pai H; Valev B; Lefresene S; Tyldesley S
JAMA Oncol; 2022 Nov; 8(11):1644-1650. PubMed ID: 36173619
[TBL] [Abstract][Full Text] [Related]
6. Quality of Life Outcomes After Stereotactic Ablative Radiation Therapy (SABR) Versus Standard of Care Treatments in the Oligometastatic Setting: A Secondary Analysis of the SABR-COMET Randomized Trial.
Olson R; Senan S; Harrow S; Gaede S; Louie A; Haasbeek C; Mulroy L; Lock M; Rodrigues G; Yaremko B; Schellenberg D; Ahmad B; Griffioen G; Senthi S; Swaminath A; Kopek N; Liu M; Moore K; Currie S; Bauman G; Warner A; Palma D
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):943-947. PubMed ID: 31470091
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.
Saad F; Thiery-Vuillemin A; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Kang J; Burgents J; Gresty C; Degboe A; Clarke NW
Lancet Oncol; 2022 Oct; 23(10):1297-1307. PubMed ID: 36063830
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic Ablative Radiation for Systemic Therapy-naïve Oligometastatic Kidney Cancer.
Hannan R; Christensen M; Christie A; Garant A; Pedrosa I; Robles L; Mannala S; Wang C; Hammers H; Arafat W; Courtney K; Bowman IA; Sher D; Ahn C; Cole S; Choy H; Timmerman R; Brugarolas J
Eur Urol Oncol; 2022 Dec; 5(6):695-703. PubMed ID: 35985982
[TBL] [Abstract][Full Text] [Related]
9. Quality of life changes after stereotactic ablative radiotherapy for liver metastases: A prospective cohort analysis.
Helou J; Thibault I; Chu W; Munoz-Schuffenegger P; Erler D; Rodrigues G; Warner A; Chan KKW; Chow E; Korol R; Davidson M; Chung HT
Radiother Oncol; 2018 Dec; 129(3):435-440. PubMed ID: 30274721
[TBL] [Abstract][Full Text] [Related]
10. Minimal clinically important differences in the EORTC QLQ-C30 and brief pain inventory in patients undergoing re-irradiation for painful bone metastases.
Raman S; Ding K; Chow E; Meyer RM; van der Linden YM; Roos D; Hartsell WF; Hoskin P; Wu JSY; Nabid A; Haas R; Wiggenraad R; Babington S; Demas WF; Wilson CF; Wong RKS; Zhu L; Brundage M
Qual Life Res; 2018 Apr; 27(4):1089-1098. PubMed ID: 29188483
[TBL] [Abstract][Full Text] [Related]
11. Systematic review of patient reported quality of life following stereotactic ablative radiotherapy for primary and metastatic liver cancer.
Mutsaers A; Greenspoon J; Walker-Dilks C; Swaminath A
Radiat Oncol; 2017 Jun; 12(1):110. PubMed ID: 28662680
[TBL] [Abstract][Full Text] [Related]
12. Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5.
Olson R; Liu M; Bergman A; Lam S; Hsu F; Mou B; Berrang T; Mestrovic A; Chng N; Hyde D; Matthews Q; Lund C; Glick D; Pai H; Basran P; Carolan H; Valev B; Lefresene S; Tyldesley S; Schellenberg D
BMC Cancer; 2018 Oct; 18(1):954. PubMed ID: 30286739
[TBL] [Abstract][Full Text] [Related]
13. Predictors of quality of life and survival following Gamma Knife surgery for lung cancer brain metastases: a prospective study.
Bragstad S; Flatebø M; Natvig GK; Eide GE; Skeie GO; Behbahani M; Pedersen PH; Enger PØ; Skeie BS
J Neurosurg; 2018 Jul; 129(1):71-83. PubMed ID: 28820304
[TBL] [Abstract][Full Text] [Related]
14. Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population-based phase II SABR-5 trial.
Eufemon Cereno R; Mou B; Baker S; Chng N; Arbour G; Bergman A; Liu M; Schellenberg D; Matthews Q; Huang V; Mestrovic A; Hyde D; Alexander A; Carolan H; Hsu F; Miller S; Atrchian S; Chan E; Ho C; Mohamed I; Lin A; Berrang T; Bang A; Jiang W; Lund C; Pai H; Valev B; Lefresne S; Tyldesley S; Olson RA
Radiother Oncol; 2023 May; 182():109576. PubMed ID: 36822355
[TBL] [Abstract][Full Text] [Related]
15. Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial.
Siva S; Bressel M; Mai T; Le H; Vinod S; de Silva H; Macdonald S; Skala M; Hardcastle N; Rezo A; Pryor D; Gill S; Higgs B; Wagenfuehr K; Montgomery R; Awad R; Chesson B; Eade T; Wong W; Sasso G; De Abreu Lourenco R; Kron T; Ball D; Neeson P;
JAMA Oncol; 2021 Oct; 7(10):1476-1485. PubMed ID: 34455431
[TBL] [Abstract][Full Text] [Related]
16. Pulmonary function and quality of life after VMAT-based stereotactic ablative radiotherapy for early stage inoperable NSCLC: a prospective study.
Ferrero C; Badellino S; Filippi AR; Focaraccio L; Giaj Levra M; Levis M; Moretto F; Torchio R; Ricardi U; Novello S
Lung Cancer; 2015 Sep; 89(3):350-6. PubMed ID: 26164208
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of stereotactic ablative radiotherapy in patients with oligometastatic hepatocellular carcinoma: A phase II study.
Choi SH; Lee BM; Kim J; Kim DY; Seong J
J Hepatol; 2024 Mar; ():. PubMed ID: 38467379
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET): Extended Long-Term Outcomes.
Harrow S; Palma DA; Olson R; Gaede S; Louie AV; Haasbeek C; Mulroy L; Lock M; Rodrigues GB; Yaremko BP; Schellenberg D; Ahmad B; Senthi S; Swaminath A; Kopek N; Liu M; Schlijper R; Bauman GS; Laba J; Qu XM; Warner A; Senan S
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):611-616. PubMed ID: 35643253
[TBL] [Abstract][Full Text] [Related]
19. Two-fraction stereotactic ablative radiotherapy (SABR) versus two-fraction high dose rate (HDR) brachytherapy for localized prostate cancer: Does dose heterogeneity matter?
Correa RJM; Morton G; Chung HT; Tseng CL; Cheung P; Chu W; Liu SK; McGuffin M; Shahid A; Davidson M; Ravi A; Helou J; Alayed Y; Zhang L; Mamedov A; Loblaw A
Radiother Oncol; 2022 Apr; 169():51-56. PubMed ID: 35151715
[TBL] [Abstract][Full Text] [Related]
20. A phase I dose-escalation trial of stereotactic ablative body radiotherapy for non-spine bone and lymph node metastases (DESTROY-trial).
Mercier C; Dirix P; Meijnders P; Vermeulen P; Van Laere S; Debois H; Huget P; Verellen D
Radiat Oncol; 2018 Aug; 13(1):152. PubMed ID: 30126440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
